Status:
RECRUITING
MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas
Lead Sponsor:
Huashan Hospital
Conditions:
Glioma
Eligibility:
All Genders
18-80 years
Brief Summary
Glioblastoma (GBM) is the most malignant primary intracranial tumor with a median survival of about 18 months, and new therapies are urgently needed. Tumor vaccines has been shown to improve survival ...
Eligibility Criteria
Inclusion
- The patients with glioma in the Department of Neurosurgery of Huashan Hospital Affiliated to Fudan University who meet the following three conditions can be enrolled
- They were 18-80 years old, male and female;
- The pathological results of frozen section during operation were gliomas (20 cases of who grade II, II and IV, respectively);
- Tissue (6 mm \* 6 mm) can be used for cell sorting on the basis of not affecting clinical routine diagnosis;
- Sign informed consent.
Exclusion
- Patients who meet any of the following criteria will not be included in this study:
- Participants in other clinical trials;
- Pregnant women.
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
360 Patients enrolled
Trial Details
Trial ID
NCT06043232
Start Date
September 1 2023
End Date
March 1 2026
Last Update
September 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Huashan Hospital，Fudan University
Shanghai, China, 200040